All In MedTech

Device Trial Radar · NCT06353594

Reduced Stent Strategy Versus Conventional Percutaneous Coronary Revascularization in Patients Presenting With STEMI

Reduced Stent Strategy Versus Conventional Percutaneous Coronary Revascularization in Patients Presenting With St-segment Elevation Myocardial Infarction (Copernican)

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,272 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,272

Planned (sponsor's estimate)

Start

Mar 11, 2024

Primary completion

Mar 2028

Study completion Sep 2035

Sponsor

Lead sponsor
Hospital Universitario La FeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
ERA4Health; ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK (ECRIN)
First posted
Apr 9, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective is to compare a reduced stent strategy based on drug-coated balloon (DCB) percutaneous coronary intervention (PCI) with conventional drug-eluting stent (DES) coronary revascularization in patients presenting with ST-segment myocardial infarction (STEMI). Randomization will be performed after successful culprit-lesion guidewire crossing and flow restoration. Random allocation in a 1:1 fashion to one of the following strategies: * Study group: reduced stent PCI strategy (DCB-based) * Control group: conventional PCI strategy (DES-based).

Conditions

  • ST Elevation Myocardial Infarction

Interventions

  • Primary PCIDevice

    Coronary percutaneous revascularization

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Target lesion failure (TLF)Time frame: 12 months

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Complejo Hospitalario Universitario de A Coruña

    A Coruña, Spain · Recruiting

22 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.